Therefore, the clinical relevance of such a decreased response remains unclear. D14, and D28). Individuals Linaclotide evaluated (= 278), including patients with rheumatoid arthritis (RA; 79), spondyloarthritis (SpA; 59), systemic sclerosis (8), systemic lupus erythematosus (SLE; 27), primary Sj?gren’s syndrome (SS; 54), and healthy controls (HC; 51). Only mild AE were reported. The frequency of local and systemic AE in patients with AID and HC did not differ significantly (8 vs. 10% and 21 vs. 32%; = 1.00 and 0.18, respectively). Patients with AID presented late seroconversion profiles according to kinetic timelines of the plaque reduction neutralization test (PRNT). PRNT-determined virus titers (copies/mL) [181 (95% confidence interval (CI), 144C228) vs. 440 (95% CI, 291C665), = 0.004] and seropositivity rate (78 vs. 96%, = 0.01) were lower in patients with AID after 28 days, particularly those with SpA (73%) Linaclotide and SLE (73%), relative to HC. The YF viremia peak (RNAnemia) was 5C6 days after vaccination in all groups. In conclusion, consistent seroconversion rates were observed in patients with AID and our findings support that planned 17DD-YF primary vaccination is safe and immunogenic in patients with AID. 0.05 were considered statistically significant. Results In total, 278 individuals were included in the study: RA (= 79), SpA (= 59), SSc (= 8), SLE (= 27), SS Linaclotide (= 54), and HC (= 51). The mean [standard deviation; SD] age of participants in the AID group was 51 (14) years and 71.8% were women. In the HC group, mean [SD] age was 56 (15) years and 56.9% were women. At baseline, all individuals were in remission, or had low disease activity, and most were under low level immunosuppression (prednisone 20 mg/day; methotrexate 20 mg/week, azathioprine 2 mg/kg/day; leflunomide, sulfasalazine, or hydroxychloroquine). Few were undergoing strong immunosuppression (16.75% of RA and 49% of SpA were receiving biological therapy; 11.11% were receiving cyclophosphamide in the SLE group; 14.81% were on high doses of prednisone or methylprednisolone; and 29.63% were receiving azathioprine). In these patients with very stable disease, biological therapy and immunosuppressive therapy were discontinued before vaccination, according to Brazilian recommendations (17). Detailed clinical features of participants are provided in Table 2. The number of participants is shown in Figure 1. Table 2 Baseline demographic, clinical, and therapeutic characteristics. 51)227)79)59)8)27)54)2.99 0.9BASDAI1.92 UCHL2 2.1CSLEDAI1.08 1.5ESSDAI1.89 3.2 Open in a separate window = 1.00 and 0.18, respectively). Table 3 Adverse events in patients with autoimmune diseases after 17DD-YF primary vaccination. 38)8 (3)C21 (8)CAID (211)21 (44)1.0032 (7)0.18????RA (75)9 (7)1.0031 (23)0.37????SpA (51)4 (2)0.6526 (13)0.80????SSC (07)14 (1)0.5057 (4)0.07????SLE (27)4 (1)0.6330 (8)0.56????SS (51)2 (1)0.1439 (20)010 Open in a separate window = 0.01). Comparative analysis of seropositivity rates among HC and AID subgroups demonstrated similar results for RA, SSC, and SS; however, lower seropositivity rates were observed in SpA (73%, = 0.02) and SLE (73%, = 0.03) relative to HC. Open in a separate window Figure 2 Seropositivity rates and PRNT levels after 17DD-YF primary vaccination in patients with AID. Levels of 17DD-YF specific neutralizing antibodies were detected by micro-PRNT, as previously described by Sim?es et al. (25). Seropositivity rates were determined with serum dilution 1:50 as the cut-off criterion for PRNT positivity (dashed line). Data are presented as bar Linaclotide charts of proportion of seropositive results at D28 according to the cut-off of 1 1:50 expressed in reverse of serum dilution for HC (), AID (), and AID subgroups (). The chi-square test was employed for comparative analysis of PRNT seropositivity rates amongst groups. The PRNT levels at D28 are expressed as geometric mean titer and 95% CI of reverse serum dilution, presented in scatter plots for HC (), AID (), RA (), SpA (), SSC (), SLE (), and.